Results 71 to 80 of about 1,633 (196)

Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed therapy of patients with malignant pleural effusion and pleural metastasis

Pleura and Peritoneum
Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) has been suggested as a new therapy for patients with malignant pleural effusion (MPE) and/or pleural metastasis (PLM). The patients have a poor prognosis with a median survival of 3 to 12 months. We
Hansen Pernille Schjødt, Graversen Martin, Detlefsen Sönke, Ainsworth Alan Patrick, Mortensen Michael Bau   +4 more
doaj   +1 more source

Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis

Therapeutic Advances in Medical Oncology, 2018
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a laparoscopy-guided administration of aerosolized chemotherapy. PIPAC seems to improve objective tumor response, survival and quality of life in patients with peritoneal metastasis.
Martin Graversen, Sönke Detlefsen, Jon Kroll Bjerregaard, Claus Wilki Fristrup, Per Pfeiffer, Michael Bau Mortensen   +5 more
doaj   +1 more source

Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC)

BMC Cancer, 2019
Background pressurized intraperitoneal aerosol chemotherapy (PIPAC), with or without electrostatic precipitation (ePIPAC), was recently introduced in the treatment of peritoneal metastases (PM) from ovarian cancer (OC).
Leen Van de Sande, Wouter Willaert, Sarah Cosyns, Kaat De Clercq, Molood Shariati, Katrien Remaut, Wim Ceelen   +6 more
doaj   +1 more source

PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

, 2018
BACKGROUND: Recurrent, platin-resistant ovarian cancer (rPROC) has a poor survival. Even with the AURELIA trial, which is the best available treatment today, progression-free survival (PFS) is still only 6.7 months from the start of the second-line ...
Scambia, Giovanni
core   +1 more source

Implementation and evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) for the treatment of patients with malignant pleural effusion: study protocol for the Danish phase-I PITAC-OPC5 study

Pleura and Peritoneum
Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) is a minimally invasive cancer-directed therapy for patients with malignant pleural effusion (MPE) and/or pleural metastasis (PLM). PITAC is based on Pressurized IntraPeritoneal Aerosol Chemotherapy,
Hansen Pernille Schjødt, Graversen Martin, Detlefsen Sönke, Ainsworth Alan Patrick, Fristrup Claus Wilki, Eckhoff Lise, Jelin-Klaric Mia, Mortensen Michael Bau   +7 more
doaj   +1 more source

Anaesthetic Considerations, Occupational Safety Measures, and 6-month Survival Rate in Patients Undergoing Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Single Institutional Experience and Review of Literature

Journal of Onco-Anaesthesiology and Perioperative Medicine
Background: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel, palliative video laparoscopic chemotherapy for reducing peritoneal metastasis in salvage situations.
Shagun Bhatia Shah, Rajiv Chawla, Nikhil Bhasin, Shaifali Goel, Shivendra Singh   +4 more
doaj   +1 more source

Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high-risk colon cancer patients - study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 Study [PDF]

, 2018
Background: Peritoneal metastasis (PM) is the second most common site of recurrence in colon cancer (CC) patients and accounts for approximately one-third of all recurrences.
Graversen, Martin, Mortensen, Michael Bau; id_orcid, Detlefsen, Sonke; id_orcid, Fristrup, Claus, Pfeiffer, Per; id_orcid   +4 more
core   +1 more source

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial

Biomedicines, 2020
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative approach for treating peritoneal carcinomatosis that applies chemotherapeutic drugs into the peritoneal cavity as an under-pressure airflow.
Michele De Simone, Marco Vaira, Monica Argenziano, Paola Berchialla, Alberto Pisacane, Armando Cinquegrana, Roberta Cavalli, Alice Borsano, Manuela Robella   +8 more
doaj   +1 more source

Comparing the cytotoxicity of taurolidine, mitomycin C, and oxaliplatin on the proliferation of in vitro colon carcinoma cells following pressurized intra-peritoneal aerosol chemotherapy (PIPAC)

World Journal of Surgical Oncology, 2019
Background Besides its known antibacterial effect commonly used in intraperitoneal lavage, taurolidine has been observed to possess antineoplastic properties.
Justyna Schubert, Veria Khosrawipour, Haris Chaudhry, Mohamed Arafkas, Wolfram Trudo Knoefel, Alessio Pigazzi, Tanja Khosrawipour   +6 more
doaj   +1 more source

Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC)

Pleura and Peritoneum, 2017
Abstract Background Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has emerged as a novel method to treat extensive, small volume peritoneal metastases. The clinical use of chemotherapy containing aerosols represents a potential occupational health hazard.
Wouter, Willaert, Paul, Sessink, Wim, Ceelen   +2 more
openaire   +2 more sources